Lilly not slashing force like its rivals

Share this article:
Eli Lilly CEO Sidney Taurel said the company does not plan any major changes to its sales force, even as rivals cut jobs.

“We won’t grow our sales force,” Taurel said in an interview with the cable network CNBC. “There has been some reduction…of our sales force. But we don’t see major decreases.”

Taurel said Lilly has already decreased its total work force by 4,500, or 10%, since 2004.

Late 2006, Pfizer announced cuts to its US and European sales forces by at least 20%. AstraZeneca said it plans to cut 3,000 jobs, or 4.6% of its workforce. Abbott also announced the phasing out of “several hundred” primary care rep positions.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in News

Email Newsletters

More in News

Five things for Pharma Marketers to know: Friday, August 29

Five things for Pharma Marketers to know: Friday, ...

Takeda closes out a good-news, bad-news kind of week, AstraZeneca adds a new clinical trial for its experimental PD-1, and researchers link a funeral to the Ebola outbreak.

Amgen sends PCSK9 to FDA

Amgen sends PCSK9 to FDA

Evolocumab holds the FDA's first filed biologics license application for the class.

Consultants expect M&A tempo to continue

Consultants expect M&A tempo to continue

PwC anticipates that divestitures will fuel late-2014 deals, but notes that the noise around early deals and the financials don't fully match up.